<DOC>
	<DOCNO>NCT01735825</DOCNO>
	<brief_summary>The purpose study compare efficacy coronary in-stent restenosis therapy use drug elute paclitaxel-coated balloon catheter late generation drug elute stent release everolimus .</brief_summary>
	<brief_title>Treatment Coronary In-Stent Restenosis</brief_title>
	<detailed_description>In-stent restenosis coronary angioplasty currently one main limitation method , lead recurrence exertional angina pectoris manifest acute coronary syndrome . Histopathologic substrate in-stent restenosis neointimal hyperplasia . Repeated plain balloon angioplasty use cut balloon catheter treatment in-stent restenosis achieve satisfactory result . Brachytherapy , use past , also abandon . The current treatment in-stent restenosis use drug elute stent . Local drug release stent prevent new neointimal hyperplasia.This treatment carry risk late thrombosis ( due delay neoendotelization ) stent strut require rigorous long-term dual antiplatelet therapy risk bleed complication . The drug-coated balloon catheter provide short-term penetration active substance vascular wall , lead inhibition hyperproliferation vascular smooth muscle cell , due short-term effect affect negatively stent strut neoendotelization . Comparable effect in-stent restenosis therapy use paclitaxel release balloon demonstrate comparison paclitaxel release stent , however , development drug elute stent meanwhile progress . The aim study compare efficacy coronary in-stent restenosis therapy use drug elute paclitaxel-coated balloon catheter late generation drug elute stent release everolimus . Primary endpoint study late lumen loss , represent accurate angiographic parameter predict need repeat revascularisation thus clinical benefit patient . The 3rd observational , non-randomised arm compare treatment seal-wing paclitaxel-eluting balloon two randomise arm ( PEB vs. EES ) .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>history percutaneous coronary intervention stent placement verify coronary instent restenosis suitable percutaneous reintervention sign informed consent contraindication long term dual antiplatelet therapy increase risk bleed know generalized malignancy pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>coronary artery disease</keyword>
	<keyword>stent</keyword>
	<keyword>restenosis</keyword>
</DOC>